ACAD Q3 2019 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$95M+62.2% YoY

Gross Profit

$90M95.0% margin

Operating Income

-$45M-48.0% margin

Net Income

-$42M-44.4% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$766M

Total Liabilities

$76M

Stockholders' Equity

$689M

Cash & Equivalents

$385M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$58M	+62.2%
Gross Profit	$90M	$53M	+69.8%
Operating Income	-$45M	-$61M	+25.9%
Net Income	-$42M	-$62M	+32.4%